Madrigal Pharmaceuticals, Inc. (MDGL) is a Biotechnology company in the Healthcare sector, currently trading at $524.99. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is MDGL = $706 (+34.4% upside).
Valuation: MDGL trades at a trailing Price-to-Earnings (P/E) of -40.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.11.
Financials: revenue is $958M, +432.1%/yr average growth. Net income is $288M (loss), growing at -4.4%/yr. Net profit margin is -30.1% (negative). Gross margin is 94.1% (-2.4 pp trend).
Balance sheet: total debt is $354M against $603M equity (Debt-to-Equity (D/E) ratio 0.59, moderate). Current ratio is 4.01 (strong liquidity). Debt-to-assets is 28.1%. Total assets: $1.3B.
Analyst outlook: 20 / 23 analysts rate MDGL as buy (87%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 96/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 67/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
